Extended-spectrum beta-lactamase-producing Enterobacteriaceae in an Italian intensive care unit: clinical and therapeutical remarks

Journal of Chemotherapy
E CarrettoP Marone

Abstract

In this study we evaluated the prevalence of Enterobacteriaceae and the epidemiology of ESBL+ microorganisms in an ICU of our Institution over a 5-year period and analyzed the clinical features and outcomes of the infections caused by these microorganisms. The most frequent ESBL+ isolate was Proteus mirabilis (69 isolates, 58%); a high rate of positive results in the double-disk synergy test (DDS) was also recognized for Klebsiella pneumoniae (52 isolates, 51%), whereas this phenomenon was observed less frequently in other species. In 312 cases the isolated microorganism was considered to be the cause of infection; we documented 103 wound infections, 89 UTIs, 62 LRTIs, 30 primary bacteremias, 27 infections of indwelling catheters and 1 CNS infection. The overall mortality rate due to ESBL+ strains was 1%, compared with 10.6% rate caused by ESBL-negative Enterobacteriaceae. This could be explained because ESBL+ strains caused mostly localized infections (wound infections and UTIs), whereas systemic or severe infections were sustained by ESBL-negative strains, and therapy with carbapenems was started promptly after ESBL+ isolation (always within 24h after strain isolation).

References

Sep 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, A A Medeiros
Aug 1, 1985·Antimicrobial Agents and Chemotherapy·C KliebeB Wiedemann
May 16, 1980·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·R P Ambler
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K BushA A Medeiros
Mar 18, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C FluitJ Verhoef
Apr 5, 2000·The Journal of Antimicrobial Chemotherapy·C de ChampsJ Sirot
Nov 30, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J A RebuckM E Rupp
Apr 5, 2002·International Journal of Antimicrobial Agents·Giovanni BonfiglioGiuseppe Nicoletti

❮ Previous
Next ❯

Citations

Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Mitchell J SchwaberYehuda Carmeli
Jul 13, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L RomeroA Pascual

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.